Amylin (Cagrilintide) (Cagrilintide)

One Cagrilintide (Amilin) 20 mg pen — ₴16,400. Standard course 4–8 weeks. Course selection — free DOZA consultation.

Cagrilintide is an amylin hormone analog. Works through separate from GLP-1 pathway: suppresses appetite via area postrema, slows gastric emptying, reduces glucagon. Result — -10.8% weight in monotherapy and up to -22.7% combined with semaglutide (CagriSema).

Yes, this is Cagrilintide's key advantage. It works through amylin receptors (separate from GLP-1), so combines with Mounjaro (tirzepatide), Ozempic/Biopatid (semaglutide/tirzepatide) and Retatrutide. In clinical study (USA, T2D) combination cagrilintide 1.2 mg + semaglutide 1.2 mg gave -15.6% weight and -2.2% HbA1c — more than semaglutide 2.4 mg alone (-5.1% weight). Novo Nordisk developed CagriSema with -22.7% result in REDEFINE-2.

Standard 16-week titration (as in Novo Nordisk Phase 3 CagriSema): weeks 1–4 — 0.25 mg/week; weeks 5–8 — 0.5 mg; weeks 9–12 — 1.0 mg; weeks 13–16 — 1.7 mg; from week 17 — maintenance 2.4 mg/week. In clinical studies maximum — 4.5 mg/week (Phase 2 mono); in CagriSema — 2.4 mg/week. If combining with Mounjaro/Ozempic — start only after GLP-1 stabilization, otherwise risk of double GI side effects. Specific dose and titration schedule for your case calculated by DOZA specialist after assessing BMI, age, existing diagnoses and current therapy.

Cagrilintide is well tolerated. Most common: nausea (10–15%), decreased appetite (desired effect), constipation/diarrhea, slow digestion, abdominal heaviness. Mild-moderate, resolve spontaneously with adaptation.

Contraindications: medullary thyroid cancer (personal or family history), MEN-2, cagrilintide allergy, intestinal obstruction, frequent gastroesophageal reflux, pregnancy, lactation. DOZA specialist checks before prescribing.

People with excess weight (even without diabetes); in type 2 diabetes — before or together with GLP-1/GIP-GLP-1 agonists (Mounjaro, Ozempic, Biopatid, Retatrutide) for improved appetite and glucose control; in type 1 diabetes — as alternative when GLP-1 medications not suitable. Also reduces cardiovascular complication risk in diabetes and CVD.

Yes. In clinical study combination cagrilintide 1.2 mg + semaglutide 1.2 mg + metformin gave average HbA1c reduction of 2.2%, fasting glucose reduction of 3.3 mmol/L and weight loss of 15.6%. This is better result than semaglutide 2.4 mg monotherapy (-1.8% HbA1c, -5.1% weight).

CagriSema (cagrilintide 2.4 + semaglutide 2.4) in REDEFINE-1 (68 weeks) gave –22.7% weight loss. Mounjaro (tirzepatide) 15 mg in SURMOUNT-1 (72 weeks) — –20.9% weight loss. So by primary endpoint CagriSema slightly outperforms Mounjaro 15 mg (~+1.8 pp). However in December 2024 Novo Nordisk published data where CagriSema showed less effect than expected (~–22.7% instead of projected –25%) — shares fell 25% in one day. Mounjaro has advantage: already FDA/EMA approved (since 2022), available from 2025 in Ukraine; CagriSema — only research-grade until 2026–2027. Practical conclusion: for first attempts — Mounjaro/Ozempic; CagriSema for those who plateau on GLP-1.

Depends on duration and dose. 16-week starter titration course (0.25→2.4 mg/week) uses total ~27 mg = 3 pens of 10 mg or 1.5 pens of 20 mg. Then maintenance 2.4 mg/week: 20 mg pen — for 8–9 weeks, 10 mg pen — for 4 weeks. For full yearly course (52 weeks) at 2.4 mg/week need ~125 mg = 7 pens of 20 mg or 13 pens of 10 mg. Exact quantity and order schedule calculated by DOZA consultant after discussing goals (short-term push, long-term maintenance, GLP-1 combination).